Short answer
UroGen Pharma Ltd. (URGN) filed an 8-K current report with the SEC on March 2, 2026 reporting Item 2.02 (Results of Operations and Financial Condition). Q4 and full-year 2025 financial results announced March 2, 2026.
UroGen Pharma Ltd. 8-K event analysis
AI summary of each reported item and its exhibits
Item 2.02 · Results of Operations and Financial Condition
- Q4 and full-year 2025 financial results announced March 2, 2026
- Full results detail contained in Exhibit 99.1 press release: primary source for revenue, earnings, and guidance figures
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other UroGen Pharma Ltd. 8-K filings
Get the next URGN 8-K as it lands
Follow URGN for push alerts, or ask the research agent what this filing means.